Cargando…
Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
T helper 2 (Th2) and T helper 1 (Th1) mediated immune processes lie on a spectrum. Autoeczematization secondary to chronic stasis dermatitis may fall on the Th2 side of the spectrum due to skin stretch and chronic barrier dysfunction, supporting a primary Th2 response to self-antigen. In our patient...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249757/ https://www.ncbi.nlm.nih.gov/pubmed/32467806 http://dx.doi.org/10.7759/cureus.7831 |
_version_ | 1783538649454870528 |
---|---|
author | Schrom, Kory P Kobs, Alison Nedorost, Susan |
author_facet | Schrom, Kory P Kobs, Alison Nedorost, Susan |
author_sort | Schrom, Kory P |
collection | PubMed |
description | T helper 2 (Th2) and T helper 1 (Th1) mediated immune processes lie on a spectrum. Autoeczematization secondary to chronic stasis dermatitis may fall on the Th2 side of the spectrum due to skin stretch and chronic barrier dysfunction, supporting a primary Th2 response to self-antigen. In our patient, we posited that dupilumab would benefit autoeczematization secondary to chronic stasis dermatitis given its efficacy in atopic dermatitis, a Th2-mediated immune process. We report a case of clinical psoriasiform dermatitis, suggesting a shift toward a Th1-mediated immune process developing during dupilumab treatment for autoeczematization secondary to chronic stasis dermatitis. |
format | Online Article Text |
id | pubmed-7249757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-72497572020-05-27 Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis Schrom, Kory P Kobs, Alison Nedorost, Susan Cureus Dermatology T helper 2 (Th2) and T helper 1 (Th1) mediated immune processes lie on a spectrum. Autoeczematization secondary to chronic stasis dermatitis may fall on the Th2 side of the spectrum due to skin stretch and chronic barrier dysfunction, supporting a primary Th2 response to self-antigen. In our patient, we posited that dupilumab would benefit autoeczematization secondary to chronic stasis dermatitis given its efficacy in atopic dermatitis, a Th2-mediated immune process. We report a case of clinical psoriasiform dermatitis, suggesting a shift toward a Th1-mediated immune process developing during dupilumab treatment for autoeczematization secondary to chronic stasis dermatitis. Cureus 2020-04-25 /pmc/articles/PMC7249757/ /pubmed/32467806 http://dx.doi.org/10.7759/cureus.7831 Text en Copyright © 2020, Schrom et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Schrom, Kory P Kobs, Alison Nedorost, Susan Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis |
title | Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis |
title_full | Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis |
title_fullStr | Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis |
title_full_unstemmed | Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis |
title_short | Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis |
title_sort | clinical psoriasiform dermatitis following dupilumab use for autoeczematization secondary to chronic stasis dermatitis |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249757/ https://www.ncbi.nlm.nih.gov/pubmed/32467806 http://dx.doi.org/10.7759/cureus.7831 |
work_keys_str_mv | AT schromkoryp clinicalpsoriasiformdermatitisfollowingdupilumabuseforautoeczematizationsecondarytochronicstasisdermatitis AT kobsalison clinicalpsoriasiformdermatitisfollowingdupilumabuseforautoeczematizationsecondarytochronicstasisdermatitis AT nedorostsusan clinicalpsoriasiformdermatitisfollowingdupilumabuseforautoeczematizationsecondarytochronicstasisdermatitis |